872365-14-5

Basic information

• Product Name: Fevipiprant
• Synonyms: Fevipiprant;Fevipipran;NVP-QAW039;Fevipiprant(NVP-QAW039);QAW039;Fevipiprant (QAW039);2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid
• CAS NO: 872365-14-5
• Molecular Formula: C19H17F3N2O4S
• Molecular Weight: 426.4094896
• Mol File: 872365-14-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 637.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: 3.33±0.30(Predicted)
• CAS DataBase Reference: Fevipiprant(CAS DataBase Reference)
• NIST Chemistry Reference: Fevipiprant(872365-14-5)
• EPA Substance Registry System: Fevipiprant(872365-14-5)

Safety Data

• Hazardous Substances Data: 872365-14-5(Hazardous Substances Data)

Usage

Uses

Fevipiprant is used in the oral treatment of asthma and has been successful in targeting severe eosinophilic asthma.Fevipiprant is a novel oral prostaglandin D2 receptor 2 (DP2; known as CRTh2) antagonist and currently in development for the treatment of severe asthma and atopic dermatitis.

Upstream product

• 41436-95-7 dimethyl 3-acetylglutarate 
• 13972-76-4 diethyl 3-acetylglutarate 
• 504-29-0 2-aminopyridine 
• 933717-06-7 2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid 
• 6302-03-0 1-(pyridin-3-yl)-2-propanone 
• 921-84-6 2-cyano-3-oxobutyric acid ethyl ester 
• 7546-50-1 2-(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid 

Relevant articles and documents

Using a Johnson-Claisen Rearrangement Strategy to Construct Azaindoles – A Streamlined and Concise Route for the Commercial Process of Fevipiprant

A novel and concise synthesis of the DP2 receptor antagonist Fevipiprant (NVP-QAW039) was developed. The initial research route was suffering from a long reaction sequence to the functionalized 7-aza-indole core followed by a poorly selective N(1)-alkylat

PREPARATION OF 2-[2-METHYL-1-[[4-METHYLSULFONYL-2-(TRIFLUORO METHYL)PHENYL]METHYL] PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID

The present invention relates to a novel compound of Formula IV and use of said compound for the preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl] methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid [fevipiprant], Formula IV wherein A is SO2Me, halogen or a leaving group. The present invention further relates to a process of preparation of pharmaceutical acceptable salts of fevipiprant and composition thereof.

PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID

This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.